Respirology Case Reports · 2018 · 44 citations · 4 references
MedicineOncologyPharmacotherapyGastrointestinal OncologyImmunotherapyInflammationCancer ImmunotherapyGastric CancerGastrointestinal ImmunologyGastrointestinal InflammationImmune-related Adverse EventsMucosal InflammationAcute Adverse EventsAutoimmune Adverse EventsEnteric InflammationGastrointestinal Inflammatory InjuryImmune Checkpoint Inhibitor TherapyImmune Checkpoint Inhibitor-related InflammationJejunal CancerSerious Adverse Events
Pembrolizumab is an immune checkpoint inhibitor that induces side effects called "immune-related adverse events" (irAEs). Various types of organs are affected by irAEs, although reports of upper gastrointestinal disorders are rare. Here, we report a case of extensive inflammatory pathologies in the oesophagus, stomach, duodenum, and jejunum after the administration of pembrolizumab for non-small cell lung cancer.
4
Severe Esophagitis and Gastritis from Nivolumab Therapy
Justin Boike, Todd J. DeJulio · ACG Case Reports Journal · 2017 · 81 citations · Full text
Medicine, Immunology, Oncology +17
Acute hemorrhagic gastritis after nivolumab treatment
Masanori Kobayashi, Ou Yamaguchi, Koji Nagata et al. · Gastrointestinal Endoscopy · 2017 · 76 citations